System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Tatsunori Shimoi

Oncology — National Cancer Center Hospital (Japan, Tokyo), Japan

LeadR Profile

Tatsunori Shimoi National Cancer Center Hospital (Japan, Tokyo) Japan
864 ScienceLeadR Reputation 864

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gynecology - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2010 - 2026
Source: PubMed

National Cancer Center Hospital (Japan, Tokyo)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 223

Citations

Citations: 1 805 1st author: 21 Last author: 0 Unique author: 4

Main journals

Ann Oncol 58
Cancer Res 12
Breast Cancer 9
BMC Cancer 7
Cancer Sci 7

Best Journals

Ann Oncol 31
J Clin Oncol 6
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Central Nervous System Symptom Burden and Clinical Implications for Antiemetic Management with Olanzapine in AC Chemotherapy.
breast neoplasms, neoplasms, drug therapy, central nervous system, vomiting, antiemetics, olanzapine, therapeutics, nervous system, chemotherapy		Oncologist20260
Dose intensity and clinical outcomes across age groups in high-grade osteosarcoma treated with methotrexate, adriamycin, and cisplatin therapy.
neoplasms, drug therapy, therapeutics, methotrexate, osteosarcoma, chemotherapy		Jpn J Clin Oncol20260
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.
safety, pharmaceutical preparations, neoplasms, biomarkers, immune checkpoint inhibitors, nivolumab, therapeutics		Cancer Sci20260
Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.
comorbidity, triple negative breast neoplasms, safety, breast neoplasms, incidence, paclitaxel, neoplasms, breast, history		NPJ Breast Cancer20260
Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.
breast neoplasms, neoplasms, classification, breast		Breast Cancer Res Treat20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 4
Phase 1 2
Phase 2 2

By status:

Active not recruiting 3
Completed 2
Recruiting 2
Terminated 1

By type:

Interventional 8

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380 — urinary bladder, carcinoma, transitional cell, urinary bladder neoplasms, cells, safety, urinary tract, neoplasms, neoplasm metastasis, carcinoma		Phase 3Recruiting2025
Induction Therapy of PTX BV Followed by Atezolizumab Nab PTX for PD L1 TNBC
NCT06793553 — triple negative breast neoplasms, breast neoplasms, paclitaxel, neoplasms, bevacizumab, immunotherapy, breast, therapeutics		Phase 2Recruiting2024
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2 Breast Cancer
NCT05132582 — injections, skin, breast neoplasms, genetics, pharmaceutical preparations, neoplasms, maintenance, breast, therapeutics, mouth, injections, subcutaneous, veins, trastuzumab, hyaluronoglucosaminidase		Phase 3Active not recruiting2022
Phase III Study to Assess AZD9833 CDK4 6 Inhibitor in HR HER2 MBC With Detectable ESR1m Before Progression (SERENA 6)
NCT04964934 — estrogen receptor antagonists, anastrozole, estrogens, aromatase, aromatase inhibitors, breast neoplasms, gonadotropin-releasing hormone, pharmaceutical preparations, receptors, estrogen, antineoplastic agents, neoplasms, luteinizing hormone, disease progression, letrozole, tablets, hormones, capsules, neoplasm metastasis, physiological effects of drugs, hormone antagonists, breast, neoplasms by site, gonadotropins, therapeutics, breast diseases, women		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS